AstraZeneca has joined the ranks of pharma companies seeking to bring drugs targeting lipoprotein(a) to market, paying $100 million upfront for rights to a drug developed by CSPC Pharmaceutical.

Radiance Biopharma Inc. bought its way into the ROR1 antibody-drug conjugate (ADC) space through a potential $1 billion-plus licensing deal, including a $15 million up-front payment, with CSPC ...

Shijiazhuang-based CSPC (OTCPK:CHJTF) said that SYS6016 has already undergone preclinical trials, neutralizing both RSV-A and RSV-B strains of the virus with a favorable safety profile.

Massachusetts-based Corbus licensed the Nectin-4-directed ADC in 2023. The deal saw China’s CSPC Pharmaceutical grant Corbus rights to the drug candidate in markets including the U.S. and the EU ...